Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%

Truist assigned Viking Therapeutics an $83 price target, implying about 188% upside from the June 8 opening price of $28.75. The bullish case centers on VK2735, Viking's obesity candidate in phase 3 for the injectable version and expected to enter phase 3 for the oral version in Q3 2026. Offsetting the upside, Viking remains pre-revenue and posted a $109 million net loss in 2024, with execution risk still high.

Analysis

VKTX is becoming a leverage play on a very specific market structure: the obesity franchise is shifting from “one-shot blockbuster” to a platform race where tolerability, dosing convenience, and label breadth determine share. If its injectable profile is genuinely differentiated, the economic upside is less about peak obesity patients and more about becoming the default prescriber choice before payers lock in preferred formularies; that creates an outsized option value versus current enterprise value, but only if the efficacy/safety package survives late-stage scrutiny.

The second-order winner set extends beyond VKTX. A credible third entrant with an oral plus injectable mix forces incumbents to defend on price, access, and physician education, which compresses margins across the category long before unit growth slows. That pressure can spill into CROs, API manufacturers, and specialty distributors as trial intensity and future commercial build-outs accelerate, while insurers and PBMs gain negotiating leverage if the market remains crowded.

The market is likely underestimating the financing and timing asymmetry. With no revenue and a cash burn rate that is accelerating, the stock can re-rate sharply on positive data but also gap down on any ambiguity, because the next 12-18 months are dominated by binary clinical and regulatory milestones rather than operating fundamentals. The key reversal trigger is not just failed efficacy; it is “good but not best-in-class” data, which is often enough to destroy scarcity value in obesity biotech.

Contrarianly, the consensus may be overweighting the size of the end market and underweighting how quickly payers can ration access once multiple GLP-1 alternatives compete for the same covered lives. A large TAM does not translate into large profits if reimbursement pushes the category toward step-edits, prior auth, and price compression. In that world, VKTX still may work as a trading vehicle, but not as a durable compounder unless it becomes one of the few drugs with measurable differentiation on both weight loss and tolerability.

Key Decisions for Investors

• Long VKTX only as a catalyst-driven position into phase 3 readouts; size for binary event risk and take partial profits on any 20-30% pre-data rerating.
• Buy VKTX call spreads instead of common for the next 6-12 months to capture upside convexity while capping downside from trial disappointment and cash-burn dilution.
• Pair trade: long VKTX / short a basket of crowded obesity winners or proxies if valuation gap widens, to isolate idiosyncratic trial upside from sector multiple compression.
• If VKTX rallies on non-incremental news, fade strength with short-dated puts or a collar; this name can lose 30-50% on “good but not enough” data.
• Monitor for financing risk over the next 12 months; any equity raise after a strong move is a potential short entry point if it resets scarcity premium lower.